Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We believe a set of positive dynamics will improve this commercial performance |
| Moreover, Eversense offers additional advantages for type 2 patients and typically prioritize simplicity, not having to replace sensors every 10 to 14 days, not having to worry about sensors frequently falling off, and the flexibility and convenience of being able to remove the transmitter as needed, are key factors contributing to type 2s now being our fastest growing segment, representing over 60% of our new patient growth |
| Most importantly, having key payer wins from 2023 in place for the full year, such as UnitedHealthcare, the establishment of a broader inserter network to make access easier, Ascensia's CGM focused organizational changes and hires together with a further build out of their commercial team, our view that this positions them more strongly to take advantage of the demand and potential for Eversense adoption |
| Encouragingly, Eversense user retention remains high |
| Financially, we achieved our full year revenue guidance and strengthened our balance sheet by reducing our debt and increasing our liquidity position |
| In continued efforts to strengthen our balance sheet in early 2024, we drew an additional $10 million on the loan facility with Hercules Capital, further enhancing our liquidity position |
| Given our product's unique advantages for the Medicare population, such as professional sensor placement, which eliminates the need for self-insertion, long sensor life, and on-body vibration alerts that serve as a secondary safety mechanism for patients, we anticipate strong adoption within this expanded Medicare population |
| We anticipate the 365-day system will offer several differentiated benefits of an implantable CGM, with a full year of protection from a single sensor and a significant reduction in calibration frequency |
| New patient starts are growing and Ascensia is on pace to exceed the total number of new patient sales in 2023 within just the first half of 2024, with new patient sales expected to grow over 150% year-over-year in the first half |
| So we're excited about the opportunity |
| Moving on to the access front, we are encouraged by the recognition from both commercial and government payers of the value that CGM brings to the broader range of patients than just those on multiple daily injections |
| He has built a reputation for successfully launching innovative products, driving revenue growth and overcoming commercial challenges within the complex durable medical equipment channel |
| This is a very important and positive step, one we believe will provide additional focus and acceleration |
| 2023 was a successful year across the business for Senseonics as we made solid progress on each of our strategic growth initiatives |
| Submission of our iCGM designation, increasing awareness of Eversense through ADC's direct-to-consumer advertising campaign and increased access with expanded coverage with UnitedHealthcare and Medicare, all while strengthening our balance sheet |
| In many of our key geographies we are seeing patient retention rates in the mid 80% range and those rates continue to improve with each subsequent sensor insertion |
| We know the features and benefits of Eversense, the longest lasting CGM available, exceptional accuracy, removable transmitter and predictive on-body alerts are resonating with patients |
| Not only is this supported by the patient retention figures, but also by the success of the direct-to-consumer marketing campaign that was launched in October |
| This highlights Eversense's unique benefits |
| With that campaign, the number of leads increased by three times, which we see as validation of strong interest in the benefits of the product |
| Every day we continue to make strong progress towards that end |
| With the increase in leads, patient enthusiasm was stronger than expected and we are very pleased to see the patient response to a campaign that better articulated unique benefits of Eversense |
| These differentiators are the basis for our belief that our 365-day system will represent a major advancement in diabetes management technology and an inflection point for Eversense in the U.S |
| As Ascensia continues to implement several commercial measures to strengthen these functions and enhance its CGM dedicated commercial infrastructure, we expect to see improved conversions going forward |
| We believe we are well positioned to grow our franchise to create shareholder value |
| Improving the patient experience is via a two-pronged strategy that is well underway |
| So we're obviously excited about that as well and looking forward to where the Ascensia to work through all of those internal systems to be much, much more effective |
| Given the inherent long-term adherence that comes with an implanted product compared to the high turnover of a weekly or biweekly transcutaneous sensors, health systems are beginning to recognize the potential for us to help their patients achieve improved outcomes, while simultaneously providing the system with the important diabetes quality measures required by their value based agreements and supporting a positive ROI from the reduced overall cost of care |
| So we're excited about those and we do fully anticipate have seen and we do fully anticipate continued improvement in that conversion |
| However, we believe Eversense holds the potential for greater growth and recognize together with Ascensia, the importance of further strengthening the commercial support Eversense receives in order to drive stronger results |
| Statement |
|---|
| Keeping in mind that Ascensia purchases will be lower in the first half than their actual patient sales given the year end conversion shortfall that they experienced |
| While the increase in lead generation clearly demonstrated and further validated the demand for our implantable CGM, significant influx of leads stressed ADC's inside sales infrastructure and processes, limiting their ability to effectively convert the leads |
| For the three months ended December 2023, total net loss was $17.2 million, or a $0.03 loss per share compared to a net income of $11.6 million or $0.02 gain per share in the fourth quarter of 2022 |
| Net income decreased by $28.8 million due to the accounting for embedded derivatives, fair value adjustments and the exchange of a portion of the 2025 Notes |
| Research and development expenses in Q4 2023 were $10.7 million, a decrease of $0.9 million compared to $11.6 million in the prior year period |
| For the three months ended December 2023, operating loss was $17 million compared to $18.9 million in the fourth quarter of 2022 due to a larger gross profit contribution and decreases in R&D and SG&A expenses |
| Fourth quarter 2023 selling, general and administrative expenses were $7.3 million, a decrease of $0.5 million compared to $7.8 million in the prior year period |
| I do want to understand though, when we've seen new products come to market, sometimes we've had a little bit of lag on reimbursement or maybe working through some inventory or a little bit of pausing as people wait for a new product |
Please consider a small donation if you think this website provides you with relevant information